ArticleJournal of virology2001
Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 67 citations in OpenAlex.
- Current State of Therapeutics for HTLV-1.Viruses · 2024Review
- Virus Safety of Xenotransplantation.Viruses · 2022Review
- Review
- PERVading strategies and infectious risk for clinical xenotransplantation.Xenotransplantation · 2018Review
- Can Antiretroviral Drugs Be Used to Treat Porcine Endogenous Retrovirus (PERV) Infection after Xenotransplantation?Viruses · 2017Review
- Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.Xenotransplantation · 2016Article
- Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.Clinical microbiology reviews · 2012Review
- Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.Journal of virology · 2011Article
- Article
- Xenotransplantation, xenogeneic infections, biotechnology, and public health.The Mount Sinai journal of medicine, New York · 2009Review
- Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.Antimicrobial agents and chemotherapy · 2007Article
- Evaluation of endogenous pig retrovirus expression and of tumorigenicity in nude mice.Veterinary research communications · 2004Article
- Characterization of two porcine endogenous retrovirus integration loci and variability in pigs.Immunogenetics · 2003Article
- Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase.Antimicrobial agents and chemotherapy · 2003Article
- Molecular and enzymatic characterization of the porcine endogenous retrovirus protease.Journal of virology · 2002Article
- Xenotransplantation-associated infectious risk: a WHO consultation.XenotransplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine xenografts may offer a solution to the shortage of human donor allografts. However, all pigs contain the porcine endogenous retrovirus (PERV), raising concerns regarding the transmission of PERV and the possible development of disease in xenotransplant recipients. We evaluated 11 antiretroviral drugs licensed for human immunodeficiency virus type 1 (HIV-1) therapy for their activities against PERV to assess their potential for clinical use. Fifty and 90% inhibitory concentrations (IC(50)s and IC(90)s, respectively) of five nucleoside reverse transcriptase inhibitors (RTIs) were determined enzymatically for PERV and for wild-type (WT) and RTI-resistant HIV-1 reference isolates. In a comparison of IC(50)s, the susceptibilities of PERV RT to lamivudine, stavudine, didanosine, zalcitabine, and zidovudine were reduced >20-fold, 26-fold, 6-fold, 4-fold, and 3-fold, respectively, compared to those of WT HIV-1. PERV was also resistant to nevirapine. Tissue culture-based, single-round infection assays using replication-competent virus confirmed the relative sensitivity of PERV to zidovudine and its resistance to all other RTIs. A Gag polyprotein-processing inhibition assay was developed and used to assess the activities of protease inhibitors against PERV. No inhibition of PERV protease was seen with saquinavir, ritonavir, indinavir, nelfinavir, or amprenavir at concentrations >200-fold the IC(50)s for WT HIV-1. Thus, following screening of many antiretroviral agents, our findings support only the potential clinical use of zidovudine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.